Neuroprotective agents
AssigneeUniversity of Kansas
InventorsMary Louise Michaelis, Ingrid Gunda Georg, Richard H. Himes, Kenneth L. Audus
Life of this patent
Estimating the term…
Abstract
Novel stereoisomers of GS-164 are provided. The compounds, such as (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol (TH-237A) and (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol (TH-242A) exhibit neuroprotective effects via a mechanism that does not involve microtubule stabilization.
Claims19
A stereomerically pure compound according to Formula I:
- wherein A and B are sulfur or oxygen;
- wherein R1 and R2 are independently halogen, alkyl, alkoxy, haloalkyl;
- and
- wherein R3 is alcohol.
A method of treating neurodegenerative disorder wherein the disorder is Alzheimer's in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of stereomerically pure compound according to Formula I:
- wherein A and B are sulfur or oxygen;
- wherein R1 and R2 are independently halogen, alkyl, alkoxy, haloalkyl;
- and
- wherein R3 is alcohol.
A pharmaceutical composition comprising stereomerically pure compound according Formula I and a pharmaceutically acceptable carrier
- wherein A and B are sulfur or oxygen;
- wherein R1 and R2 are independently halogen, alkyl, alkoxy, haloalkyl;
- and
- wherein R3 is alcohol.
A pharmaceutical composition comprising stereomerically pure compound according the following formula and a pharmaceutically acceptable carrier wherein the carrier is a cyclodextrin,
- wherein A and B are sulfur or oxygen;
- wherein R1 and R2 are independently halogen, alkyl, alkoxy, haloalkyl;
- and
- wherein R3 is alcohol.
Dependencies are inferred from the claim text.